Welcome to our dedicated page for PolyPid Ltd. SEC filings (Ticker: PYPD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PolyPid Ltd. filings document foreign private issuer disclosures for a biopharmaceutical company developing PLEX-based controlled-release therapeutics. Form 6-K reports furnish corporate updates, financial results, FDA and NDA-related disclosures for D-PLEX100, SHIELD II clinical and pharmacokinetic information, GMP inspection updates, and business-operation summaries.
The company’s regulatory record also covers capital-structure and governance matters, including ordinary-share sales agreement disclosures, legal opinions tied to share issuance, Form F-3 and Form S-8 registration statement references, shareholder meeting results, board composition, director compensation approvals, and risk and operating disclosures incorporated into its SEC registration framework.
PolyPid Ltd., an Israel-based biopharmaceutical company, filed a Form 6-K to furnish a press release announcing the appointment of Dr. Nurit Tweezer-Zaks as its Chief Medical Officer. This leadership change relates to oversight of the company’s medical and clinical activities.
The filing also states that the first and third paragraphs of the press release, along with its “Forward-Looking Statements” section, are incorporated by reference into several of PolyPid’s effective registration statements on Forms F-3 and S-8, so that these disclosures become part of those offering documents going forward.
PolyPid held its Annual and Extraordinary General Meeting on June 25, 2025, where shareholders approved all seven proposed resolutions. Key approvals include:
- Re-appointment of Kost Forer Gabbay & Kasierer as independent auditors
- Re-election of eight board members with approved compensation
- New option grants for non-executive directors
- Two separate option grants for CEO Dikla Czaczkes Akselbrad: - Standard option grant - Additional milestone-based option grant
- Renewal of company's compensation policy
- Acceleration of unvested options for departing Board Chairman Jacob Harel
The meeting also included discussion of financial statements for FY2024. The approved changes to compensation and governance structure indicate strategic moves to retain leadership and align management incentives with company performance. The filing was incorporated into multiple Form F-3 and S-8 registration statements.
PolyPid, an Israeli biotechnology company established over five years ago, has filed Form D to report an exempt securities offering under Rule 506(b). The company has successfully completed a $26,692,799 offering, with all securities now sold to 20 investors.
The offering includes equity securities, along with options/warrants and their underlying securities. The company, which currently reports no revenues, maintains its principal operations at 18 Hasivim Street, Petach Tikva, Israel.
Key management includes:
- Four executive officers: Dikla Czaczkes Akselbrad, Dalit Hazan, Ori Warshavsky, and Jonny Missulawin
- Eight independent directors including Jacob Harel, Yechezkel Barenholz, and others
The offering involves no sales commissions or finder's fees, and none of the proceeds are designated for payments to executives or directors. The offering is not connected to any business combination transaction and is not intended to last more than one year.